UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Methods for High-throughput Drug Combination Screening and Synergy Scoring

Methods in molecular biology (Clifton, N.J.), 2018-01, Vol.1711, p.351

2018

Volltextzugriff (PDF)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

Scientific reports, 2014-06, Vol.4 (1), p.5193-5193, Article 5193

2014

Volltextzugriff (PDF)

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Science translational medicine, 2018-07, Vol.10 (450)

2018

Volltextzugriff (PDF)

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

The Journal of biological chemistry, 2020-03, Vol.295 (13), p.4194-4211

2020

Volltextzugriff (PDF)

HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix

Scientific reports, 2016-09, Vol.6 (1), p.33916-33916, Article 33916

2016

Volltextzugriff (PDF)

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

BMC cancer, 2019-06, Vol.19 (1), p.628-628, Article 628

2019

Volltextzugriff (PDF)

Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin

The Journal of cell biology, 2011-01, Vol.192 (1), p.153-169

2011

Volltextzugriff (PDF)

Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages

Molecular & cellular proteomics, 2016-10, Vol.15 (10), p.3203-3219

2016

Volltextzugriff (PDF)

Antifungal Application of Nonantifungal Drugs

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.1055-1062

2014

Volltextzugriff (PDF)

Identification and Tracking of Antiviral Drug Combinations

Viruses, 2020-10, Vol.12 (10), p.1178

2020

Volltextzugriff (PDF)

Anagrelide for Gastrointestinal Stromal Tumor

Clinical cancer research, 2019-03, Vol.25 (5), p.1676-1687

2019

Volltextzugriff (PDF)

N-syndecan deficiency impairs neural migration in brain

The Journal of cell biology, 2006-08, Vol.174 (4), p.569-580

2006

Volltextzugriff (PDF)

High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro

Biomolecules (Basel, Switzerland), 2020-09, Vol.10 (10), p.1365

2020

Volltextzugriff (PDF)

Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome

Translational oncology, 2022-12, Vol.26, p.101535-101535, Article 101535

2022

Volltextzugriff (PDF)

HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiation

Scientific reports, 2016-09, Vol.6 (1), p.32960-32960, Article 32960

2016

Volltextzugriff (PDF)

Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma

PloS one, 2013-09, Vol.8 (9), p.e73072

2013

Volltextzugriff (PDF)

Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Clinical and translational medicine, 2019-12, Vol.8 (1), p.1-15

2019

Volltextzugriff (PDF)

Expression of the recombinant antibacterial peptide sarcotoxin IA in Escherichia coli cells

Protein expression and purification, 2003-04, Vol.28 (2), p.350-356

2003

Volltextzugriff (PDF)

Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy

Molecular cancer therapeutics, 2018-09, Vol.17 (9), p.2060-2071

2018

Volltextzugriff (PDF)

TBIO-18. ESTABLISHING A PIPELINE FOR INDIVIDUALIZED TREATMENT OPTIONS FOR PEDIATRIC BRAIN CANCER

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Supplement_3), p.iii470-iii470

2020

Volltextzugriff (PDF)

Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing

Journal of Laboratory Automation, 2016-02, Vol.21 (1), p.27-36

2016

Volltextzugriff (PDF)

Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments

Briefings in bioinformatics, 2022-01, Vol.23 (1)

2022

Volltextzugriff (PDF)

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells

Gynecologic oncology, 2017-03, Vol.144 (3), p.621-630

2017

Volltextzugriff (PDF)

Abstract 5328: Protein phosphatase 2A activity is a major determinant of therapy response in cancer cells

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5328-5328

2015

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(47)

Sprache

Englisch
(46)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(21)
Humans
(14)
Oncology
(8)
Antineoplastic Agents - Pharmacology
(7)
Biochemistry & Molecular Biology
(7)
Animals
(6)
Cell Line, Tumor
(6)
Mice
(6)
Biochemical Research Methods
(5)
Cancer
(4)
Cell Survival - Drug Effects
(4)
Drug Screening
(4)
Medicin Och Hälsovetenskap
(4)
Multidisciplinary Sciences
(4)
Science & Technology - Other Topics
(4)
Signal Transduction - Drug Effects
(4)
Cell Biology
(3)
Cell Line
(3)
Clinical Trials
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Methods for High-throughput Drug Combination Screening and Synergy Scoring

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin

Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages

Antifungal Application of Nonantifungal Drugs

Identification and Tracking of Antiviral Drug Combinations

Anagrelide for Gastrointestinal Stromal Tumor

N-syndecan deficiency impairs neural migration in brain

High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro

Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome

HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiation

Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma

Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Expression of the recombinant antibacterial peptide sarcotoxin IA in Escherichia coli cells

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia

Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy

TBIO-18. ESTABLISHING A PIPELINE FOR INDIVIDUALIZED TREATMENT OPTIONS FOR PEDIATRIC BRAIN CANCER

Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing

Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells

Abstract 5328: Protein phosphatase 2A activity is a major determinant of therapy response in cancer cells

Suchergebnisse filtern